Patents by Inventor Peter Mohr

Peter Mohr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6890947
    Abstract: Compounds of formula I are provided as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R8, A, A1 and n have the significance indicated in the specification.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: May 10, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alfred Binggeli, Beat Wirz, Uwe Grether, Hans Hilpert, Roland Humm, Hans Iding, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Publication number: 20050096336
    Abstract: There are presented compounds of the formula wherein R6 and R7 is R4 and R5 or R5 and R6 together with the carbon atoms to which they are attached, form a ring as defined in the description and X1, X2, Y1 to Y4, R1 to R13 and n are as specified in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 5, 2005
    Inventors: Jean Ackermann, Johannes Aebi, Alfred Binggeli, Uwe Grether, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Matthew Wright
  • Publication number: 20050096337
    Abstract: This invention relates to compounds of the formula wherein one of R5, R6 and R7 is and X1, X2, Y1 to Y4, R1 to R13 and m and n are defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 5, 2005
    Inventors: Jean Ackermann, Johannes Aebi, Alfred Binggeli, Uwe Grether, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Matthew Wright
  • Publication number: 20050096353
    Abstract: This invention relates to compounds of the formula wherein one of R6, R7 and R8 is and X, Y1 to Y4, R1 to R14 and n are as defined in the description, and to all enantiomers and pharmaceutically acceptable salts and/or esters thereof The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.
    Type: Application
    Filed: October 29, 2004
    Publication date: May 5, 2005
    Inventors: Jean Ackermann, Johannes Aebi, Alfred Binggeli, Uwe Grether, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Matthew Blake Wright
  • Publication number: 20050004187
    Abstract: This invention relates to compounds of the formula wherein one of R6, R7 or R8 is and all enantiomers and pharmaceutically acceptable salts and/or esters thereof as well as pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR? and/or PPAR? agonists.
    Type: Application
    Filed: June 28, 2004
    Publication date: January 6, 2005
    Inventors: Jean Ackermann, Johannes Aebi, Alfred Binggeli, Uwe Grether, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Matthew Wright
  • Publication number: 20040248951
    Abstract: This invention relates to compounds of the formula 1
    Type: Application
    Filed: June 1, 2004
    Publication date: December 9, 2004
    Inventors: Jean Ackermann, Johannes Aebi, Alfred Binggeli, Uwe Grether, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Mathew Blake Wright
  • Patent number: 6821980
    Abstract: The invention relates to substituted 5-benzyl-2,4-diaminopyrimidines of general formula (A) wherein R1 is C2-C3 alkyl an R2 is heterocyclyl, phenyl or naphthyl, bonded by one of its C-atoms and R3 is C2-C6 alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, heterocyclylalkyl, alkylsulfonyl, cycloalkylsulfonyl, cycloalkylalkylsulfamoyl, heterocyclysylfonyl, heterocyclylalkylsulfonyl or dialkylsulfamoyl; wherein alkyl, cycloalkyl and alyenyl can carry up to 6 carbon atoms alone or in compositions and can carry up to 6 ring members heterocyclically, alone, or in compositions and the groups R2 and R3 can be substituted; and to acid addition salts of compounds. The invention also relates to a method for producing the above 5-benzyl-2,4-diaminopyrimidines, to the intermediate. products that are produced, to corresponding medicaments and to the use of 5-benzyl-2,4-diaminopyrimidines as medicinal preparations.
    Type: Grant
    Filed: July 18, 2002
    Date of Patent: November 23, 2004
    Assignee: Basilea Pharmaceutica AG
    Inventors: Philippe Guerry, Peter Mohr, Marc Muller, Werner Mueller, Philippe Pflieger
  • Patent number: 6818649
    Abstract: This invention is concerned with substituted chromene derivatives of the general formula (I) in which R1-R4 are as defined in the specification and claims. The invention further relates to the pharmaceutically acceptable acid addition salts of these compounds, their use as therapeutically active substances; medicaments based on these substances, optionally in combination with sulphonamides, and their production; the use of these substances as medicaments and for the production of antibacterially-active medicaments; as well as the manufacture of the compounds of formula (I) and their pharmaceutically acceptable acid addition salts and intermediates for their manufacture.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: November 16, 2004
    Assignee: Basilea Pharmaceutica AG
    Inventors: Peter Mohr, Philippe Pflieger
  • Patent number: 6809110
    Abstract: The present invention provides compounds of formula (I) wherein R1 to R10, X, Y and n are indicated in the specification, and pharmaceutically acceptable salts and esters thereof. The compounds are useful for the treatment of non-insulin dependent diabetes mellitus.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: October 26, 2004
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alfred Binggeli, Uwe Grether, Hans Hilpert, Georges Hirth, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Publication number: 20040157898
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: November 4, 2003
    Publication date: August 12, 2004
    Inventors: Alfred Binggeli, Uwe Grether, Hans Hilpert, Georges Hirth, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Publication number: 20040116487
    Abstract: The present invention relates to compounds of formula (I) 1
    Type: Application
    Filed: October 6, 2003
    Publication date: June 17, 2004
    Inventors: Alfred Binggeli, Markus Boehringer, Uwe Grether, Hans Hilpert, Georges Hirth, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Fabienne Ricklin
  • Publication number: 20040110807
    Abstract: The present invention provides compounds of formula (I) 1
    Type: Application
    Filed: August 28, 2003
    Publication date: June 10, 2004
    Inventors: Alfred Binggeli, Uwe Grether, Hans Hilpert, Georges Hirth, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Publication number: 20040106657
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: November 21, 2003
    Publication date: June 3, 2004
    Inventors: Alfred Binggeli, Uwe Grether, Hans Hilpert, Georges Hirth, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Publication number: 20040077728
    Abstract: Disclosed are retiferol derivatives of formula (I): wherein X is >C═CH2 or —CH2—; Y and Z are independently of each other hydrogen, fluorine or hydroxy; A is —O(CH2)3—, —(CH2)2-(1,2-C6H4)—, —CH═CH—(1,2-C6H4)—, —C═C—(1,2C6H4)—, —(CH2)2—CO—, —CH2—O—CO—, —CH2NHCO—, or —CH2NHCOCH2—; R1 is C1-C5-alkyl; R2 and R3 are independently of each other alkyl or perfluoroalkyl; and R4 is hydrogen, hydroxy, C1-C5-alkyl or C1-C5-alkyl or C1-C5-alkoxy; the use of such compounds to treat or present hyperproliferative skin diseases such as psoriasis, basal cell carcinomas, disorders of keratinization and keratosis; neoplastic diseases; disorders of the sebaceous glands such as acne and seborrhoic dermatitis; the use of these compounds in reversing the conditions associated with photodamage, particularly for the oral or topical treatment of the skin damaged through sun exposur
    Type: Application
    Filed: December 4, 2003
    Publication date: April 22, 2004
    Inventors: Pierre Barbier, Franz W Bauer, Peter Mohr, Marc Muller, Wolfgang Pirson
  • Publication number: 20040053979
    Abstract: Compounds of formula I are provided 1
    Type: Application
    Filed: September 10, 2003
    Publication date: March 18, 2004
    Inventors: Alfred Binggeli, Beat Wirz, Uwe Grether, Hans Hilpert, Roland Humm, Hans Iding, Bernd Kuhn, Hans-Peter Maerki, Markus Meyer, Peter Mohr
  • Patent number: 6642389
    Abstract: The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: November 4, 2003
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alfred Binggeli, Markus Boehringer, Uwe Grether, Hans Hilpert, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Fabienne Ricklin
  • Patent number: 6610877
    Abstract: Compounds of the formula wherein R1 is a residue of the formula and R2-R10 have the significance given in the specification can be used as pharmaceuticals, particularly for the repair of photodamaged skin, other dermatological conditions, and oncological indications.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: August 26, 2003
    Assignee: Hoffman-La Roche Inc.
    Inventors: Michael Klaus, Peter Mohr
  • Publication number: 20030144246
    Abstract: This invention is concerned with substituted chromene derivatives of the general formula (I) in which R1 represents alkyl or cycloalkylalkyl, R2 and R3 each independently represent alkyl or cycloalkyl or taken together with the adjacent carbon atom represent a saturated 3- to 6-membered carbocyclic or heterocyclic ring, the alkyl, cycloalkyl, carbocyclic or heterocyclic ring being unsubstituted or substituted, and R4 represents hydrogen, halogen cyano, alkyl, alkylthio, alkenyl, alkynyl, hydroxyalkyl, hydroxyalkynyl, alkoxyalkyl, alkoxyalkynyl, trialkylsilyl, aryl or heteroaryl, and pharmaceutically acceptable acid addition salts of these compounds, their use as therapeutically active substances; medicaments based on these substances, optionally in combination with sulphonamides, and their production; the use of these substances as medicaments and for the production of antibacterially-active medicaments; as well as the manufacture of the compounds of formula (I) and their pharmaceutically acceptable acid addi
    Type: Application
    Filed: October 28, 2002
    Publication date: July 31, 2003
    Inventors: Peter Mohr, Philippe Pflieger
  • Publication number: 20030055265
    Abstract: The present invention relates to novel oxazole compounds which act as PPAR&agr; and PPAR&ggr; agonists and are accordingly useful for the treatment of diseases modulated by PPAR&agr; and PPAR&ggr; such as diabetes.
    Type: Application
    Filed: May 9, 2002
    Publication date: March 20, 2003
    Inventors: Alfred Binggeli, Markus Boehringer, Uwe Grether, Hans Hilpert, Hans-Peter Maerki, Markus Meyer, Peter Mohr, Fabienne Ricklin
  • Patent number: 6479670
    Abstract: This invention relates to new selective retinoid acid receptor agonists of formula I wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
    Type: Grant
    Filed: July 12, 2000
    Date of Patent: November 12, 2002
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Paula Nanette Belloni, Peter Mohr